Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis.

Fagan AM, Christopher E, Taylor JW, Parsadanian M, Spinner M, Watson M, Fryer JD, Wahrle S, Bales KR, Paul SM, Holtzman DM.

Am J Pathol. 2004 Oct;165(4):1413-22.

2.

Aging, gender and APOE isotype modulate metabolism of Alzheimer's Abeta peptides and F-isoprostanes in the absence of detectable amyloid deposits.

Yao J, Petanceska SS, Montine TJ, Holtzman DM, Schmidt SD, Parker CA, Callahan MJ, Lipinski WJ, Bisgaier CL, Turner BA, Nixon RA, Martins RN, Ouimet C, Smith JD, Davies P, Laska E, Ehrlich ME, Walker LC, Mathews PM, Gandy S.

J Neurochem. 2004 Aug;90(4):1011-8.

3.

A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model.

Hurtado DE, Molina-Porcel L, Iba M, Aboagye AK, Paul SM, Trojanowski JQ, Lee VM.

Am J Pathol. 2010 Oct;177(4):1977-88. doi: 10.2353/ajpath.2010.100346. Epub 2010 Aug 27.

4.

Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model.

Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K, Pappolla MA.

Neurobiol Dis. 2000 Aug;7(4):321-31. Erratum in: Neurobiol Dis 2000 Dec;7(6 Pt B):690.

PMID:
10964604
5.

Independent effects of APOE on cholesterol metabolism and brain Abeta levels in an Alzheimer disease mouse model.

Mann KM, Thorngate FE, Katoh-Fukui Y, Hamanaka H, Williams DL, Fujita S, Lamb BT.

Hum Mol Genet. 2004 Sep 1;13(17):1959-68. Epub 2004 Jun 30.

6.

Braak staging in mouse models of Alzheimer's disease.

Granic I, Masman MF, Luiten PG, Eisel UL.

Am J Pathol. 2010 Oct;177(4):1603-5. doi: 10.2353/ajpath.2010.100656. Epub 2010 Sep 2.

7.

Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease.

Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM.

J Biol Chem. 2005 Dec 30;280(52):43236-42. Epub 2005 Oct 5.

8.
9.

Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease.

Paris D, Ganey NJ, Laporte V, Patel NS, Beaulieu-Abdelahad D, Bachmeier C, March A, Ait-Ghezala G, Mullan MJ.

J Neuroinflammation. 2010 Mar 8;7:17. doi: 10.1186/1742-2094-7-17.

10.

Changes in apolipoprotein E expression in response to dietary and pharmacological modulation of cholesterol.

Petanceska SS, DeRosa S, Sharma A, Diaz N, Duff K, Tint SG, Refolo LM, Pappolla M.

J Mol Neurosci. 2003;20(3):395-406.

PMID:
14501024
11.

Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis.

Praticò D, Uryu K, Leight S, Trojanoswki JQ, Lee VM.

J Neurosci. 2001 Jun 15;21(12):4183-7.

12.
13.

Deletion of Abca7 increases cerebral amyloid-β accumulation in the J20 mouse model of Alzheimer's disease.

Kim WS, Li H, Ruberu K, Chan S, Elliott DA, Low JK, Cheng D, Karl T, Garner B.

J Neurosci. 2013 Mar 6;33(10):4387-94. doi: 10.1523/JNEUROSCI.4165-12.2013.

14.

Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease.

Hartman RE, Laurer H, Longhi L, Bales KR, Paul SM, McIntosh TK, Holtzman DM.

J Neurosci. 2002 Dec 1;22(23):10083-7.

15.

Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice.

Cao D, Fukuchi K, Wan H, Kim H, Li L.

Neurobiol Aging. 2006 Nov;27(11):1632-43. Epub 2005 Oct 19.

PMID:
16236385
16.

Acceleration of brain amyloidosis in an Alzheimer's disease mouse model by a folate, vitamin B6 and B12-deficient diet.

Zhuo JM, Praticò D.

Exp Gerontol. 2010 Mar;45(3):195-201. doi: 10.1016/j.exger.2009.12.005. Epub 2009 Dec 11.

17.

Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.

DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM.

Science. 2002 Mar 22;295(5563):2264-7.

18.

Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid beta peptide levels.

Pacheco-Quinto J, Rodriguez de Turco EB, DeRosa S, Howard A, Cruz-Sanchez F, Sambamurti K, Refolo L, Petanceska S, Pappolla MA.

Neurobiol Dis. 2006 Jun;22(3):651-6. Epub 2006 Mar 3.

PMID:
16516482
19.

Probucol suppresses enterocytic accumulation of amyloid-β induced by saturated fat and cholesterol feeding.

Pallebage-Gamarallage MM, Galloway S, Takechi R, Dhaliwal S, Mamo JC.

Lipids. 2012 Jan;47(1):27-34. doi: 10.1007/s11745-011-3595-4. Epub 2011 Jul 31.

PMID:
21805327
20.

A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease.

Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, Tint GS, Wang R, Mercken M, Petanceska SS, Duff KE.

Neurobiol Dis. 2001 Oct;8(5):890-9.

PMID:
11592856
Items per page

Supplemental Content

Write to the Help Desk